For example, SHP2 mutations in tumor cells induce Erk inhibitor resistance through feedback activation of receptor tyrosine kinase (RTK) signaling and rebounding of Erk activity in Erk-driven tumors (Ahmed et al., 2019). This evidence concerns the gene PTPN11 and neoplasm.